Cell manufacturing solutions that nurture the future
EME leverages its proprietary VHH agonist technology to develop next-generation cell manufacturing solutions in the fields of cell and gene therapy and regenerative medicine.
Currently, many cell culture processes utilize cytokines and growth factors, but these face challenges such as manufacturing costs, stability, and supply. At EME, we are promoting the development of new solutions that evolve the cell manufacturing process itself, based on the functional antibody creation technology we have cultivated through drug discovery support.
1. Development Concept
Development of growth factor/growth factor substitutes
Growth factors such as FGF, HGF, and EGF play crucial roles in the culture of stem cells and cells used in regenerative medicine. At EME, we are working on developing growth factor substitute molecules by utilizing VHH agonist technology that targets receptor tyrosine kinases (RTKs).
Development of cytokine substitutes
Cytokines such as IL-2 and IL-15 are widely used in the production processes of T cells and NK cells. EME aims to improve the efficiency of immune cell culture processes and create new cell manufacturing technologies through the development of VHH agonists that directly activate cytokine receptors.
Application of antibody molecular engineering technology
To achieve the activity and sustained action required for cell culture applications, EME utilizes molecular engineering technologies such as multivalent formulation, bispecification, Fc fusion, and half-life extension design for VHH antibodies. We emphasize functional design that controls cellular responses, rather than simply achieving receptor binding.
2. Product Lineup
(Highly stable growth factor surrogate antibody) FGF2 surrogate VHH agonist antibody
We also offer samples of various FGF2-substitute VHH antibodies for cell culture.
3. Sample provision and information request
EME is not only utilizing antibodies as pharmaceuticals, but also challenging itself to create new bioprocesses by using them as functional molecules that support cell manufacturing.
We aim to build a next-generation platform that will contribute to the advancement of cell and gene therapy and regenerative medicine.
*Some of the technologies and concepts presented are currently under research and development.
This document outlines our development policy and does not guarantee the timing of product release or availability.